Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety
- 35 Downloads
We describe the short- and long-term outcomes for PDAC patients after tailored mesopancreas dissection using supracolic artery-first approach followed by adjuvant therapy.
This study analyzed 233 consecutive patients who underwent artery-first pancreaticoduodenectomy for PDAC. Dissection extent for the superior mesenteric artery (SMA) was categorized into three levels: level 2 (LV2) including regional lymph nodes, level 3 (LV3) with hemicircumferential nerve plexus dissection, and extended-level 3 (E-LV3) including borderline resectable cases for the SMA. All clinical, pathological, and survival outcomes were reviewed.
LV2/3/E-LV3 dissection was performed in 77/115/41 patients. The short-term outcomes were similar among groups without mortality. Although postoperative diarrhea requiring opioids was significantly more frequent in the E-LV3 group (76%) than other groups (vs. LV2 (21%), P < .0001; vs. LV3 (34%), P < .0001; LV2 vs. LV3, P = 0.20), most cases of diarrhea were well controlled. Adjuvant chemotherapy was introduced similarly among groups (LV2, 76%; LV3, 81%; E-LV3, 88%, P = 0.29). The 3- and 5-year overall survival rates in the LV2/3/E-LV3 groups were 42/33/42% and 27/22/26%, respectively, showing no significant difference among groups.
Our tailored dissection and preemptive use of opioid antidiarrheal effectively prevents intractable diarrhea, increasing the success of adjuvant chemotherapy.
KeywordsPancreaticoduodenectomy Artery first Superior mesenteric artery Diarrhea Adjuvant therapy
superior mesenteric artery
pancreatic ductal adenocarcinoma
the nerve plexus around the SMA
postoperative pancreatic fistula
delayed gastric emptying
We thank Mr. Koki Tazoe (a free graphic designer, Nerima-ku, Tokyo) for the valuable edition of digital illustration as schemata in the article.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 10.Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada Y et al. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci. 2012;19(3):230–41.CrossRefGoogle Scholar
- 11.Japan pancreas Society. General Rules for the Study of Pancreatic Cancer ( The 7th Edition). 2016.Google Scholar
- 12.Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248–57. doi: https://doi.org/10.1016/s0140-6736(16)30583-9.CrossRefPubMedGoogle Scholar
- 13.Network NCC. Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma. 2015.Google Scholar
- 14.Verbeke CS. Operative specimen handling an evaluation of resection margins. In: Kim SW, Yamaue H, eds Pancreatic cancer with special focus on topical issues and surgical techniques Heiderberg: Springer. 2017:67–87.Google Scholar
- 24.Farnell MB, Pearson RK, Sarr MG, Di Magno EP, Burgart LJ, Dahl TR et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery. 2005;138(4):618–28; discussion 28–30. https://doi.org/10.1016/j.surg.2005.06.044.CrossRefPubMedGoogle Scholar
- 26.Nguyen TC, Sohn TA, Cameron JL, Lillemoe KD, Campbell KA, Coleman J et al. Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J Gastrointest Surg. 2003;7(1):1–9;CrossRefGoogle Scholar
- 27.Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH et al. Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Ann Surg. 2018;267(5):936–945.Google Scholar
- 37.Jang JY, Kang MJ, Heo JS, Choi SH, Choi DW, Park SJ et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg. 2014;259(4):656–64.CrossRefGoogle Scholar
- 44.Takahashi H, Akita H, Tomokuni A, Kobayashi S, Ohigashi H, Fijiwara Y et al. Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence. Ann Surg. 2016;264(6):1091–7.CrossRefGoogle Scholar